Abbott Laboratories Current Ratio 2012-2025 | ABT
Current and historical current ratio for Abbott Laboratories (ABT) from 2012 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Abbott Laboratories current ratio for the three months ending December 31, 2025 was 0.00.
| Abbott Laboratories Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-12-31 | $0.00B | 0.00 | |
| 2025-09-30 | $24.84B | $14.58B | 1.70 |
| 2025-06-30 | $24.47B | $13.44B | 1.82 |
| 2025-03-31 | $23.15B | $13.00B | 1.78 |
| 2024-12-31 | $23.66B | $14.16B | 1.67 |
| 2024-09-30 | $23.80B | $14.90B | 1.60 |
| 2024-06-30 | $23.12B | $13.76B | 1.68 |
| 2024-03-31 | $22.38B | $14.02B | 1.60 |
| 2023-12-31 | $22.67B | $13.84B | 1.64 |
| 2023-09-30 | $22.66B | $13.04B | 1.74 |
| 2023-06-30 | $23.51B | $14.35B | 1.64 |
| 2023-03-31 | $24.38B | $14.53B | 1.68 |
| 2022-12-31 | $25.22B | $15.49B | 1.63 |
| 2022-09-30 | $24.85B | $13.37B | 1.86 |
| 2022-06-30 | $24.96B | $12.39B | 2.01 |
| 2022-03-31 | $23.43B | $12.65B | 1.85 |
| 2021-12-31 | $24.24B | $13.11B | 1.85 |
| 2021-09-30 | $23.49B | $12.87B | 1.83 |
| 2021-06-30 | $22.63B | $12.61B | 1.79 |
| 2021-03-31 | $21.82B | $12.46B | 1.75 |
| 2020-12-31 | $20.44B | $11.91B | 1.72 |
| 2020-09-30 | $17.39B | $10.26B | 1.70 |
| 2020-06-30 | $17.22B | $10.96B | 1.57 |
| 2020-03-31 | $15.50B | $10.81B | 1.43 |
| 2019-12-31 | $15.67B | $10.86B | 1.44 |
| 2019-09-30 | $16.12B | $10.49B | 1.54 |
| 2019-06-30 | $15.20B | $9.06B | 1.68 |
| 2019-03-31 | $14.41B | $9.11B | 1.58 |
| 2018-12-31 | $14.63B | $9.01B | 1.62 |
| 2018-09-30 | $18.20B | $12.78B | 1.42 |
| 2018-06-30 | $14.12B | $8.95B | 1.58 |
| 2018-03-31 | $14.96B | $9.01B | 1.66 |
| 2017-12-31 | $20.15B | $8.91B | 2.26 |
| 2017-09-30 | $21.38B | $7.94B | 2.69 |
| 2017-06-30 | $19.98B | $6.80B | 2.94 |
| 2017-03-31 | $19.33B | $6.65B | 2.91 |
| 2016-12-31 | $26.78B | $6.66B | 4.02 |
| 2016-09-30 | $12.98B | $8.32B | 1.56 |
| 2016-06-30 | $12.99B | $8.67B | 1.50 |
| 2016-03-31 | $12.41B | $8.39B | 1.48 |
| 2015-12-31 | $14.16B | $9.19B | 1.54 |
| 2015-09-30 | $15.89B | $8.76B | 1.82 |
| 2015-06-30 | $21.13B | $9.19B | 2.30 |
| 2015-03-31 | $19.99B | $9.21B | 2.17 |
| 2014-12-31 | $13.56B | $10.47B | 1.30 |
| 2014-09-30 | $16.46B | $10.82B | 1.52 |
| 2014-06-30 | $18.26B | $9.85B | 1.85 |
| 2014-03-31 | $17.93B | $10.19B | 1.76 |
| 2013-12-31 | $19.25B | $9.51B | 2.03 |
| 2013-09-30 | $19.75B | $11.33B | 1.74 |
| 2013-06-30 | $19.83B | $10.92B | 1.82 |
| 2013-03-31 | $19.10B | $10.41B | 1.84 |
| 2012-12-31 | $31.32B | $13.28B | 2.36 |
| 2012-09-30 | $27.26B | $16.29B | 1.67 |
| 2012-06-30 | $26.26B | $17.12B | 1.53 |
| 2012-03-31 | $25.60B | $16.79B | 1.53 |
| 2011-12-31 | $23.77B | $15.48B | 1.54 |
| 2011-09-30 | $23.09B | $15.41B | 1.50 |
| 2011-06-30 | $24.13B | $15.84B | 1.52 |
| 2011-03-31 | $23.65B | $17.23B | 1.37 |
| 2010-12-31 | $22.32B | $17.26B | 1.29 |
| 2010-09-30 | $19.45B | $15.58B | 1.25 |
| 2010-06-30 | $19.92B | $14.69B | 1.36 |
| 2010-03-31 | $17.69B | $15.18B | 1.17 |
| 2009-12-31 | $23.31B | $13.05B | 1.79 |
| 2009-09-30 | $21.42B | $12.53B | 1.71 |
| 2009-06-30 | $19.63B | $12.04B | 1.63 |
| 2009-03-31 | $18.01B | $11.77B | 1.53 |
| 2008-12-31 | $17.04B | $11.59B | 1.47 |
| 2008-09-30 | $15.23B | $9.56B | 1.59 |
| 2008-06-30 | $16.96B | $12.02B | 1.41 |
| 2008-03-31 | $15.11B | $10.77B | 1.40 |
| 2007-12-31 | $14.04B | $9.10B | 1.54 |
| 2007-09-30 | $12.84B | $12.28B | 1.05 |
| 2007-06-30 | $12.34B | $12.01B | 1.03 |
| 2007-03-31 | $11.50B | $12.31B | 0.94 |
| 2006-12-31 | $11.28B | $11.95B | 0.94 |
| 2006-09-30 | $10.07B | $7.43B | 1.36 |
| 2006-06-30 | $9.90B | $7.69B | 1.29 |
| 2006-03-31 | $10.61B | $7.16B | 1.48 |
| 2005-12-31 | $11.39B | $7.42B | 1.54 |
| 2005-09-30 | $10.99B | $8.76B | 1.26 |
| 2005-06-30 | $9.66B | $6.08B | 1.59 |
| 2005-03-31 | $10.35B | $7.37B | 1.41 |
| 2004-12-31 | $10.73B | $6.83B | 1.57 |
| 2004-09-30 | $10.22B | $7.30B | 1.40 |
| 2004-06-30 | $10.50B | $7.62B | 1.38 |
| 2004-03-31 | $10.94B | $6.95B | 1.57 |
| 2003-12-31 | $9.61B | $6.96B | 1.38 |
| 2003-09-30 | $10.26B | $8.04B | 1.28 |
| 2003-06-30 | $9.72B | $7.33B | 1.33 |
| 2003-03-31 | $9.43B | $6.94B | 1.36 |
| 2002-12-31 | $8.46B | $6.34B | 1.34 |
| 2002-09-30 | $8.48B | $6.72B | 1.26 |
| 2002-06-30 | $8.01B | $6.87B | 1.17 |
| 2002-03-31 | $8.08B | $6.95B | 1.16 |
| 2001-12-31 | $8.42B | $7.93B | 1.06 |
| 2001-09-30 | $8.17B | $7.78B | 1.05 |
| 2001-06-30 | $7.96B | $7.41B | 1.08 |
| 2001-03-31 | $8.19B | $10.89B | 0.75 |
| 2000-12-31 | $7.38B | $4.30B | 1.72 |
| 2000-09-30 | $6.97B | $4.28B | 1.63 |
| 2000-06-30 | $6.90B | $4.19B | 1.65 |
| 2000-03-31 | $6.73B | $4.50B | 1.50 |
| 1999-12-31 | $6.42B | $4.52B | 1.42 |
| 1999-09-30 | $5.88B | $4.33B | 1.36 |
| 1999-06-30 | $5.55B | $4.17B | 1.33 |
| 1999-03-31 | $5.77B | $4.71B | 1.23 |
| 1998-12-31 | $5.55B | $4.96B | 1.12 |
| 1998-09-30 | $5.07B | $4.67B | 1.09 |
| 1998-06-30 | $5.18B | $5.00B | 1.04 |
| 1998-03-31 | $5.18B | $4.73B | 1.10 |
| 1997-12-31 | $5.04B | $5.03B | 1.00 |
| 1997-09-30 | $4.65B | $4.72B | 0.99 |
| 1997-06-30 | $4.59B | $4.51B | 1.02 |
| 1997-03-31 | $4.63B | $4.38B | 1.06 |
| 1996-12-31 | $4.48B | $4.34B | 1.03 |
| 1996-09-30 | $4.27B | $4.29B | 1.00 |
| 1996-06-30 | $4.33B | $4.53B | 0.96 |
| 1996-03-31 | $4.11B | $3.49B | 1.18 |
| 1995-12-31 | $4.23B | $3.79B | 1.12 |
| 1995-09-30 | $4.08B | $3.57B | 1.14 |
| 1995-06-30 | $4.04B | $3.54B | 1.14 |
| 1995-03-31 | $3.89B | $3.59B | 1.08 |
| 1994-12-31 | $3.88B | $3.48B | 1.12 |
| 1994-09-30 | $3.86B | $3.41B | 1.13 |
| 1994-06-30 | $3.72B | $3.27B | 1.14 |
| 1994-03-31 | $3.52B | $3.05B | 1.15 |
| 1993-12-31 | $3.59B | $3.10B | 1.16 |
| 1993-09-30 | $3.55B | $3.12B | 1.14 |
| 1993-06-30 | $3.45B | $3.06B | 1.13 |
| 1993-03-31 | $3.35B | $3.00B | 1.12 |
| 1992-12-31 | $3.23B | $2.78B | 1.16 |
| 1992-09-30 | $3.30B | $2.68B | 1.23 |
| 1992-06-30 | $3.03B | $2.32B | 1.31 |
| 1992-03-31 | $2.93B | $2.25B | 1.30 |
| 1991-12-31 | $2.89B | $2.23B | 1.30 |
| 1991-09-30 | $2.72B | $2.06B | 1.32 |
| 1991-06-30 | $2.73B | $2.07B | 1.32 |
| 1991-03-31 | $2.68B | $2.04B | 1.31 |
| 1990-12-31 | $2.46B | $2.00B | 1.23 |
| 1990-09-30 | $2.69B | $2.18B | 1.24 |
| 1990-06-30 | $2.50B | $1.90B | 1.32 |
| 1990-03-31 | $2.32B | $1.66B | 1.40 |
| 1989-12-31 | $2.10B | $1.38B | 1.52 |
| 1989-09-30 | $2.37B | $1.64B | 1.45 |
| 1989-06-30 | $2.27B | $1.43B | 1.58 |
| 1989-03-31 | $2.20B | $1.28B | 1.71 |
| 1988-12-31 | $2.35B | $1.44B | 1.63 |
| 1988-09-30 | $2.20B | $1.42B | 1.55 |
| 1988-06-30 | $2.22B | $1.44B | 1.54 |
| 1988-03-31 | $2.12B | $1.45B | 1.46 |
| 1987-12-31 | $2.16B | $1.49B | 1.45 |
| 1987-09-30 | $2.01B | $1.37B | 1.46 |
| 1987-06-30 | $1.99B | $1.37B | 1.46 |
| 1987-03-31 | $1.97B | $1.32B | 1.49 |
| 1986-12-31 | $1.89B | $1.30B | 1.45 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $189.676B | $44.328B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EssilorLuxottica (ESLOY) | France | $140.849B | 0.00 |
| Stryker (SYK) | United States | $138.598B | 26.59 |
| Medtronic (MDT) | Ireland | $131.983B | 18.29 |
| Boston Scientific (BSX) | United States | $115.097B | 25.46 |
| Medline (MDLN) | United States | $60.694B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.604B | 0.00 |
| ResMed (RMD) | United States | $38.903B | 25.98 |
| GE HealthCare Technologies (GEHC) | United States | $37.513B | 17.97 |
| Agilent Technologies (A) | United States | $36.753B | 23.23 |
| Koninklijke Philips (PHG) | Netherlands | $27.809B | 18.16 |
| Terumo (TRUMY) | Japan | $18.896B | 21.35 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.585B | 10.97 |
| Insulet (PODD) | United States | $17.105B | 53.09 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.943B | 0.00 |
| Baxter (BAX) | United States | $11.191B | 9.03 |
| Sunny Optical Technology (SNPTF) | China | $8.485B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.080B | 29.05 |
| Demant (WILYY) | Denmark | $6.521B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.301B | 13.10 |
| Envista Holdings (NVST) | United States | $4.063B | 20.59 |
| BillionToOne (BLLN) | United States | $3.897B | 0.00 |
| ICU Medical (ICUI) | United States | $3.694B | 23.45 |
| Prestige Consumer Healthcare (PBH) | United States | $3.152B | 14.63 |
| Haemonetics (HAE) | United States | $3.044B | 13.22 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.014B | 0.00 |
| Neogen (NEOG) | United States | $2.304B | 50.43 |
| Phibro Animal Health (PAHC) | United States | $2.027B | 17.86 |
| LeMaitre Vascular (LMAT) | United States | $1.973B | 39.72 |
| Perrigo (PRGO) | Ireland | $1.964B | 4.92 |
| QuidelOrtho (QDEL) | United States | $1.949B | 12.53 |
| AtriCure (ATRC) | United States | $1.800B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.466B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.466B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.421B | 20.57 |
| Green Thumb Industries (GTBIF) | United States | $1.417B | 62.09 |
| BioLife Solutions (BLFS) | United States | $1.060B | 314.57 |
| Capricor Therapeutics (CAPR) | United States | $1.053B | 0.00 |
| Lumexa Imaging Holdings (LMRI) | United States | $0.959B | 0.00 |
| InMode (INMD) | Israel | $0.937B | 10.59 |
| Tilray Brands (TLRY) | Canada | $0.821B | 0.00 |
| Valneva SE (VALN) | France | $0.803B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.790B | 0.00 |
| Omeros (OMER) | United States | $0.761B | 0.00 |
| CeriBell (CBLL) | United States | $0.717B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.578B | 15.66 |
| Verano Holdings (VRNO) | United States | $0.447B | 0.00 |
| Cerus (CERS) | United States | $0.411B | 0.00 |
| Brainsway (BWAY) | Israel | $0.410B | 69.77 |
| Canopy Growth (CGC) | Canada | $0.398B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.361B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.326B | 26.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.309B | 0.00 |
| Evolus (EOLS) | United States | $0.286B | 0.00 |
| Quanterix (QTRX) | United States | $0.275B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.234B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.219B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Utah Medical Products (UTMD) | United States | $0.201B | 18.06 |
| Organigram Global (OGI) | Canada | $0.200B | 0.00 |
| High Tide (HITI) | Canada | $0.200B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.196B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.191B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.188B | 55.17 |
| Sanara MedTech (SMTI) | United States | $0.178B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.175B | 0.00 |
| Accendra Health (ACH) | United States | $0.170B | 1.71 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Apyx Medical (APYX) | United States | $0.151B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.146B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.129B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.69 |
| MacroGenics (MGNX) | United States | $0.108B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.104B | 0.00 |
| Biote (BTMD) | United States | $0.097B | 4.24 |
| Exagen (XGN) | United States | $0.076B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 23.49 |
| Sharps Technology (STSS) | United States | $0.041B | 0.00 |
| Nephros (NEPH) | United States | $0.041B | 29.85 |
| Cytosorbents (CTSO) | United States | $0.040B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.039B | 0.00 |
| Veru (VERU) | United States | $0.036B | 0.00 |
| Modular Medical (MODD) | United States | $0.034B | 0.00 |
| United-Guardian (UG) | United States | $0.033B | 16.63 |
| Jin Medical (ZJYL) | China | $0.022B | 0.00 |
| Bonk (BNKK) | United States | $0.019B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| INLIF (INLF) | China | $0.010B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| ZeroStack (ZSTK) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |